Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

StemCells acquires key patents from University of Calgary

This article was originally published in Clinica

Executive Summary

StemCells Inc of Newark, California has acquired a portfolio of US and Canadian patents with expiration dates as far out as 2024, which previously were licensed from the University of Calgary. The company will issue 139,548 shares of StemCells common stock to Neurospheres Holdings, the university's intellectual property holding company. The acquisition relieves StemCells of all milestone and royalty obligations under prior license agreements for products claimed by the patents, such as the company's proprietary purified human neural stem cells (HuCNS-SC).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT101028

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel